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Abstract
The insulin-like growth factor (IGF) system mediates growth, differentiation and developmental
processes; it is also involved in various metabolic activities. Deregulation of IGF system expression
and action is linked to diverse pathologies, ranging from growth deficits to cancer development.
Targeting of the IGF axis emerged in recent years as a promising therapeutic approach in cancer
and other medical conditions. Rational use of IGF-I-induced gene signatures may help to identify
patients who might benefit from IGF axis-directed therapeutic modalities. In the accompanying
research article in BMC Medicine, Rajski et al. show that IGF-I-induced gene expression in primary
breast and lung fibroblasts accurately predict outcomes in breast and lung cancer patients.
See the associated research paper by Rajski et al: http://www.biomedcentral.com/1741-7015/8/1
Introduction
The vast amount of information that has been generated
in recent years, following the elucidation of the human
genome, is changing our current views on most biological
processes. Genomic and proteomic approaches, as well as
other high-throughput platforms, are having a huge
impact on our understanding of both basic and clinical
questions. This 'gain-of-knowledge' is particularly mani-
fest in the field of cancer research, where physiological
and pathological processes are now amenable for integra-
tive examination at multiple levels of analysis. The insu-
lin-like growth factors (IGFs) are a collection of cellular
and secreted factors with vital roles in cell biology. The
IGF system consists of two ligands (IGF-I and IGF-II), two
receptors [IGF-IR and IGF-II/mannose 6-phosphate recep-
tor (M6P-R)] and at least six IGF-binding proteins
(IGFBPs) [1-3]. In addition, the IGF network includes a
series of IGFBP-related proteins and IGFBP proteases
which are responsible for cleaving IGFBPs and, thus,
releasing the free ligands. The IGF-IR, which mediates
most of the biological actions of both IGF-I and IGF-II, is
linked to the ras-raf-MAPK and PI3K-Akt signalling cas-
cades [4,5].
The proliferative and antiapoptotic actions of IGF-I have
been well characterized [6-8]. Although IGF-I, per se, is
usually regarded as non-genotoxic (that is, it cannot
induce mutations or cause transformation), once a malig-
nant event has occurred, cell survival of already trans-
formed cells depends to a large extent on IGF-I action.
Breast tumours express all of the components of the IGF
system, including ligands, receptors and IGFBPs [9].
Serum IGF-I stimulates breast cancer proliferation in an
endocrine fashion. In addition, stromal cells adjacent to
the malignant cells also produce IGF-I which acts in a
paracrine manner. Breast cancer cells, themselves, pro-
duce mainly IGF-II. The importance of IGF action in can-
cer biology is supported by epidemiological studies
showing a correlation between circulating IGF-I and can-
cer incidence. In a prospective nested control study (the
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Nurse's Health Study, published in 1998) the relative risk
of breast cancer in premenopausal women was shown to
be 4.6 in the upper tertile of IGF-I values in comparison to
women in the lower tertile [10]. These seminal studies
have been replicated over the last 10 years by numerous
groups worldwide. Systematic reviews of the literature and
meta analyses conclude, for the most part, that high circu-
lating IGF-I concentrations are associated with an
increased risk of premenopausal breast cancer, although
the relative risks were substantially lower than those
reported in early studies [11].
In recent years, the IGF system emerged as a promising
interventional target in cancer therapy and major transla-
tional efforts are currently aimed at identifying and opti-
mizing therapeutic tools directed against this growth
factor system [12-14]. It is, therefore, crucial to identify
IGF-I-induced genes that can predict clinical outcome in
breast and other types of cancer.
Discussion
This month in BMC Medicine, a paper by Rajski et al. [15]
deals with the potential role of IGF-I-induced genes in pri-
mary breast and lung fibroblasts as predictors of outcome
in breast and lung cancer patients. This report provides a
comprehensive, yet highly focused, analysis of the poten-
tial clinical significance of IGF-I-induced signatures. Spe-
cifically, the authors used an ex vivo culture model and
measured gene expression changes after IGF-I stimulation
with cDNA microarrays. Using a series of bioinformatic
tools (GO TermFinder, TreeView softwares, and others)
they analysed the in vitro microarray data and compared it
with published expression datasets on human cancer
biopsies.
Characterization of IGF-I-induced genes in CCL-171
human primary fibroblasts detected an increase (greater
than 1.5-fold change) in the expression levels of 370
genes. This fibroblast derived IGF-I signature was enriched
for genes involved in biological processes such as mitotic
cell cycle, angiogenesis, p53 pathway, integrin and Wnt
signalling. IGF-I stimulation of MCF-7 breast cancer cells
induced expression of genes involved in tumour biology
(including the vascular endothelial growth factor) as well
as genes involved in protein metabolism. In contrast to
the upregulation of genes involved in proliferation
observed in CCL-171 fibroblasts, the gene expression pat-
tern in MCF-7 cells was not associated with cell cycle or
proliferation.
In order to test the hypothesis that mesenchymal stromal
cells and malignant epithelial cells exhibit distinct gene
expression changes in response to IGF-I stimulation, the
gene expression profiles of CCL-171 and MCF-7 cells,
with and without IGF-I stimulation, were compared. Hier-
archical clustering of the genes indicate that, when epithe-
lial and mesenchymal cells are exposed to IGF-I, they
show some concordant and some discordant gene expres-
sion changes. Genes that are upregulated in CCL-171 cells
and downregulated in MCF-7 cells belong mainly to the
Wnt and TGF-β signalling families and nucleic acid bind-
ing proteins. Genes that are upregulated in MCF-7 and
downregulated in CCL-171 cells are mainly involved in
protein metabolism and modification, as well as nucleo-
side, nucleotide and nucleic acid metabolism.
Carcinoma associated fibroblasts (CAF) and normal
fibroblasts were obtained from three breast cancer
patients, cultured and separated with magnetic beads tar-
geting fibroblast-specific antigens. Both CAF and normal
fibroblasts were then treated with IGF-I and gene expres-
sion profiles were generated. Two hundred and eight
genes were shown to be upregulated by IGF-I and they
were used to create the breast fibroblast derived IGF-I sig-
nature. The genes upregulated by IGF-I in primary fibrob-
lasts share similar features to those elevated in CCL-171
fibroblast cultures. Contrary to the authors' expectations,
they did not find any significant difference in the response
to IGF-I between CAF and normal fibroblasts.
In order to verify the relevance of their in vitro data, the
authors checked the expression of the breast fibroblast
derived IGF-I signature in microarray data of early stage
breast cancer biopsies from 295 patients. Interestingly,
patients with a high expression level of this signature had
a higher risk of developing metastases than patients with
low expression levels. In addition, the overall survival rate
was lower for patients with upregulated breast fibroblast
derived IGF-I signature. The authors also show that the
breast fibroblast derived IGF-I signature could segregate
oestrogen receptor (ER) positive patients into two groups
with significantly different clinical outcomes. Interest-
ingly, patients with upregulation of this signature and ER
negative status had the worse outcomes. The clinical cor-
relation of the IGF-I signature should be further investi-
gated, since it might have an important clinical
application in treatment tailoring of breast cancer
patients.
Finally, the breast fibroblast derived IGF-I signature was
also positively correlated to previously published gene
expression signatures, including the wound signature
which was created based on the response of fibroblasts to
serum stimulation [16]. In addition, the signature was
inversely correlated to the good-risk 70-genes signature,
which was created in order to predict freedom from
metastasis [17]. The fibroblast derived IGF-I signature was
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Conclusions
The study by Rajski et al. highlights the impact of novel
profiling technologies on our ability to identify respond-
ers to specific targeted treatments. The IGF-I-induced sig-
natures in primary breast and lung fibroblasts are similar
to each other and also to previously published signatures,
suggesting that these findings can be generalized to addi-
tional types of tumours. As indicated by the authors, the
consistent response of fibroblasts to IGF-I might explain
the worse outcome of patients with elevated circulating
IGF-I values. Finally, and given the inconsistent correla-
tion between IGF-IR expression and patient outcome in
breast cancer [18], the IGF-I-induced signature might be
of relevance for selecting patients who might benefit from
IGF-IR blocking therapies.
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